• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Seagen Inc.

    12/26/23 6:12:25 AM ET
    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGEN alert in real time by email
    15-12G 1 d669576d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 0-32405

     

     

    SEAGEN INC.

    (Exact name of registrant as specified in its charter)

     

     

    21823 30th Drive SE

    Bothell, WA 98021

    (425) 527-4000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: One

     

     

     


    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Seagen Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    SEAGEN INC.
    By:  

    /s/ Margaret M. Madden

    Name:   Margaret M. Madden
    Title:   Vice President

    Date: December 26, 2023

    Get the next $SGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGEN

    DatePrice TargetRatingAnalyst
    2/16/2023$140.00 → $175.00In-line → Outperform
    Evercore ISI
    2/16/2023$155.00 → $175.00Outperform → Strong Buy
    Raymond James
    2/6/2023$162.00 → $141.00Outperform → Market Perform
    SVB Securities
    11/21/2022$135.00Hold
    Truist
    10/11/2022$177.00 → $178.00Market Perform → Outperform
    BMO Capital Markets
    6/29/2022$220.00Outperform
    Raymond James
    6/24/2022$169.00Market Perform
    BMO Capital Markets
    2/16/2022$201.00 → $142.00Market Outperform
    JMP Securities
    More analyst ratings

    $SGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/18/23 6:46:48 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:55:41 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:46:58 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care